Neupharma and Rare Partners are pleased to announce their collaboration in the development of projects in the field of lung infections caused by methicillin-resistant Staphylococcus Aureus (MRSA). The collaboration between Neupharma and Rare Partners initially focused on Cystic Fibrosis, a genetic disease to which Neupharma has been dedicating its efforts for years. On 23 August 2017, the European Commission granted Neupharma the designation of an orphan drug for the use of Teicoplanin in the treatment of cystic fibrosis.
In particular, the designation is for an aerosol formulation of Teicoplanin for the treatment of MRSA lung infections in patients suffering from cystic fibrosis, a potentially life-threatening pathology. Fabio Borella, President of Neupharma, said: "Obtaining the Orphan Drug Designation is an important step and a precious acknowledgement of the value of the project.
Lung infections sustained by resistant germs and in particular by MRSA are a significant emergency in the population affected by cystic fibrosis. Neupharma has a leading position in the inhalation treatment of lung infections in Italy thanks to its partnership with important international players. This project will allow Neupharma to have its own product distributed throughout the EU." According to Marco Prosdocimi, Managing Director of Rare Partners, "This important result was made possible thanks to the collaboration we have established with such an important partner as Neupharma. Neupharma is a referent point in our country for the doctors in front line in the treatment of respiratory infections, cystic fibrosis in particular. We are confident that this result can increase the attractiveness of collaboration with us as a way to advance experimental research results towards clinical application.”